A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC

Recruiting now · Not applicable

Conditions studied: Early Hepatocellular Carcinoma

In brief

This Phase II Prospective, parallel and open-label randomised control trial will investigate whether a radiotherapy technique (called SABR) can treat early stage liver cancer more effectively than current treatments which use heating probes directly inserted into the tumour or chemotherapy or radioactive particles injected into the blood supply of the tumour. Investigators hypothesize SABR will result in higher rates of freedom from local progression (FFLP) at 2 years compared to percutaneous thermal ablation ± TACE or transarterial therapies (TACE/TARE).The study will also look at other important outcomes such as progression free survival, overall survival, side effects, quality of life and people's experiences of their treatment.

Key facts

Study ID

NCT07628751

Run by

University Health Network, Toronto

People needed

218

Starts

2026-05-11

Expected to finish

2032-04-01

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histological or radiological diagnosis of single, new HCC with largest diameter =8 cm (BCLC stage 0 or A).
• a) If prior history of HCC, the prior HCC must have been:
• Early stage, solitary HCC, =5 cm in size and,
• Have arisen within a different liver segment to the current HCC and,
• Treated with curative intent therapy >2 years prior with no evidence of active disease at the site.
• 2) As per local multidisciplinary HCC meeting consensus patient is suitable for percutaneous thermal ablation and/or transarterial therapies and not suitable for or declined liver resection and not planned for liver transplantation.
• 3) Child-Pugh score =B7* with no or diuretic-controlled ascites
• 4) ECOG performance status =2
• 5) Platelets =50x109/L, Haemoglobin =80 g/L, Neutrophils =1.0x109/L, INR <1.8 (except if on therapeutic anticoagulation)
• 6) 18 years of age or older and able to provide written consent

You may not qualify if…

• 1) Presence of multifocal HCC, macrovascular invasion or extrahepatic disease
• 2) Prior treatment for any HCC within last 2 years.
• 3) Clinically evident ascites or hepatic encephalopathy
• 4) Prior abdominal radiation therapy that would preclude the delivery of protocol defined SABR to the tumour.
• 5) Untreated Hepatitis B or C
• 6) Known additional invasive malignancy (excluding non-melanoma skin cancer) that is progressing or required treatment within the last 2 years.
• 7) Pregnancy

Where it is running

• Trans Tasman Radiation Oncology Group — Waratah, Australia (enrolling)
• University Health Network - Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.